Showing 1 - 9 results of 9 for search 'Javier Ruiz-Guiñazú', query time: 0.05s Refine Results
  1. 1
    Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage

    Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage by Christopher Clarke, Lauren O. Bakaletz, Javier Ruiz-Guiñazú, Dorota Borys, Tomas Mrkvan

    Published 2017-07-01
    Get full text
    Article
  2. 2
    Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience

    Effectiveness and impact of the 10-valent pneumococcal conjugate vaccine, PHiD-CV: review of clinical trials and post-marketing experience by Tomas Mrkvan, Stephen I. Pelton, Javier Ruiz-Guiñazú, Arto A. Palmu, Dorota Borys

    Published 2018-09-01
    Get full text
    Article
  3. 3
    Development of patient- and observer-reported outcome measures to assess COVID-19 signs and symptoms in children and adolescents

    Development of patient- and observer-reported outcome measures to assess COVID-19 signs and symptoms in children and adolescents by Carla Romano, Margaret Mayorga, Javier Ruiz-Guiñazú, Géralyn C. Trudel, Sheri Fehnel, Kelly McQuarrie, Eric K. H. Chan, Eva G. Katz

    Published 2023-01-01
    Get full text
    Article
  4. 4
    Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans

    Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans by Anna Dari, Philippe Jacqmin, Yuki Iwaki, Martine Neyens, Mathieu Le Gars, Jerald Sadoff, Karin Hardt, Javier Ruiz‐Guiñazú, Juan José Pérez‐Ruixo

    Published 2023-10-01
    Get full text
    Article
  5. 5
    Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial

    Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial by Jelena Tica, Veronica V. Rezelj, Benoit Baron, Vitalija van Paassen, Javier Zaidman, Lee Fairlie, Gert Scheper, Mathieu Le Gars, Frank Struyf, Macaya Douoguih, Javier Ruiz-Guiñazú

    Published 2025-12-01
    Get full text
    Article
  6. 6
    Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial

    Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a ph... by Shabir A Madhi, Anthonet Koen, Lisa Jose, Marta Moreira, Nadia van Niekerk, Clare Cutland, Nancy François, Javier Ruiz-Guiñazú, Juan Pablo Yarzabal, Dorota Borys, Lode Schuerman

    Published 2017-06-01
    Get full text
    Article
  7. 7
    Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial

    Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial by Veronica V. Rezelj, Fred Paddenburg, Marie Enajite Diegbe, Julius Nangosyah, Emil C. Reisinger, Weihong Hu, Carla Truyers, Gert Scheper, Mathieu Le Gars, Jenny Hendriks, Frank Struyf, Macaya Douoguih, Hanneke Schuitemaker, Javier Ruiz-Guiñazú

    Published 2024-10-01
    Get full text
    Article
  8. 8
    Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – A randomized controlled trial

    Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – A... by Xavier Sáez-Llorens, Stella Rowley, Digna Wong, Mirna Rodríguez, Arlene Calvo, Marisol Troitiño, Albino Salas, Vielka Vega, Maria Mercedes Castrejón, Patricia Lommel, Thierry G. Pascal, William P. Hausdorff, Dorota Borys, Javier Ruiz-Guiñazú, Eduardo Ortega-Barría, Juan Pablo Yarzabal, Lode Schuerman

    Published 2017-06-01
    Get full text
    Article
  9. 9
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context

    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised co... by Gabriela Tapia-Calle, Gloria Aguilar, Nathalie Vaissiere, Carla Truyers, Pedro Ylisastigui, Erik Buntinx, Mathieu Le Gars, Frank Struyf, Gert Scheper, Macaya Douoguih, Javier Ruiz-Guiñazú, Robert Patrizi, Wai Ling, Sanne de Ridder, Marit de Groot, Maria Grazia Pau, Gerald Weidinger, Srividya Pradeep, Nadine Salisch, Sophie Cambre

    Published 2025-01-01
    Get full text
    Article

Search Tools: